Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

business remains solid. We continue to invest in our pipeline while simultaneously generating strong sales, earnings, and cash flow."

The company is updating its guidance for 2008. Total sales guidance is increased to $1.90 - $1.94 billion. This includes CNS franchise sales of $1.02 - $1.04 billion, pain franchise sales of $500 - $520 million, oncology franchise sales of $175 - $185 million, and other product sales of $200 - $210 million. Full year SG&A and R&D guidance is $800 - $815 million and $340 - $355 million, respectively. Adjusted net income guidance for 2008 is $354 - $360 million and basic adjusted income per common share guidance is increased by $0.10 per share to $5.20 - $5.30.

Cephalon is introducing 2009 sales guidance of $2.175 - $2.225 billion. This includes CNS franchise sales of $1.15 - $1.18 billion, pain franchise sales of $535 - $560 million, oncology franchise sales of $265 - $280 million, and other product sales of $180 - $205 million. SG&A and R&D guidance for 2009 are $840 - $860 million and $390 - $410 million, respectively.

The company also is introducing adjusted net income guidance for 2009 of $452 - $459 million. This represents growth of approximately 27 percent over our increased 2008 guidance. Cephalon is introducing 2009 basic adjusted income per common share guidance of $6.50 - $6.60.

Basic adjusted income per common share guidance for both the full-year 2008 and full-year 2009 is reconciled below and is subject to the assumptions set forth therein.

Cephalon's management will discuss the company's third quarter 2008 performance in a conference call with investors beginning at 5:00 p.m. U.S. EDT today. To participate in the conference call, dial +1-913-312-9315 and refer to conference code number 8454517. Investors can listen to the call live by logging on to the company's website at http://www.cephalon.com and clicking on "Investor Information,
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... A recent study from researchers in ... find that those who took probiotics were able to run ... study showed that in extreme heat conditions, probiotics were able ... acne treatment explains what this new discovery means ... their skin condition. , While researchers tote the benefits ...
(Date:5/21/2013)... -- First patients dosed with PSX1002, an ... using Prosonix, particle engineering platform Prosonix, an ... Respiratory Medicines by Design , has initiated a ... its effect on lung function and the safety of ... severe chronic obstructive pulmonary disease (COPD). The first two ...
(Date:5/21/2013)... May 21, 2013 Custom Learning ... reporting eLearning solution using Tin Can API combined ... tool. CLD is a leading developer of training ... device companies worldwide. , Tin Can API ... helps learners and trainers more accurately measure the ...
(Date:5/21/2013)... Alpha Source, Inc., a Wisconsin-based ... exhibiting for the 13th consecutive year at the ... 2013 Conference and Expo. The conference brings together ... healthcare technologies. This year’s event will be held ... , The three-day event draws over 1,500 healthcare ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2
... It's been a long campaign season, and you've been poked ... national press corps member. John Kerry drank a beer at ... at your local kindergarten. Dick Cheney was spotted more in ... in the last four years. John Edwards has been in ...
... drug purification products Business filings serves ... dip in third-quarter earnings from mild weather ... Wisconsin-based Analogix joins French company to ... maker of drug-purification devices based in Burlington, Wisconsin, has ...
... more hours in the day so I can get more done (like ... We "fall back" into standard time and get another hour. But what ... my desk, which I always promise to do when I have more ... wanted to share in this column. Here they are, in no particular ...
Cached Biology Technology:Twenty ways you can tell this campaign has finally pushed you over the edge 2Tech Digest: whats moving in the Midwest (11/1/04) 2Music, mail, databases and printing from a technologists desk 2Music, mail, databases and printing from a technologists desk 3
(Date:5/21/2013)... The largest gathering of biomass experts , ... , When? 03-07 June 2013 ... scientific research, resource assessment, market and policy developments, manufacturing ... the world and benefiting from its 2013 edition from ... more than 60 countries, more than 240 plenary and ...
(Date:5/21/2013)... May 21, 2013 Royal Philips Electronics (NYSE: ... world,s first portable ultrasound with Philips, industry leading Live ... The CX50 xMATRIX with available Live 3D TEE and ... at the EuroPCR, official meeting for the European ... Since its launch in 2012, Philips CX50 xMATRIX ...
(Date:5/20/2013)... antibiotic colistin are also commonly resistant to antimicrobial ... a study in mBio , the online ... Cross-resistance to colistin and host antimicrobials LL-37 and ... attack, could mean that patients with life-threatening multi-drug ... immune response. Colistin is a last-line drug for ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... Alabama used worms to reel in information that they hope ... may be exploited to treat epilepsy. In a new research ... the researchers explain how the transparent roundworm, C. elegans ... transport of a molecule (gamma-aminobutyric acid or "GABA") that if ...
... b3c newswire / - Critical Outcome Technologies ... from animal experiments carried out at a prominent Canadian ... to the already impressive data package for COTI-2, demonstrating ... first line therapies with low toxicity in seven different ...
... the primary cause of cancer mortality in children. Even ... tremendously from the stressful treatment which can be harmful ... need for target-oriented, gentle treatment methods. The most important ... approximately one hundred young patients each year in Germany, ...
Cached Biology News:More than fish bait: Worms unlock secrets to new epilepsy treatments 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 4Germany starts its part in the International Cancer Genome Project 2Germany starts its part in the International Cancer Genome Project 3Germany starts its part in the International Cancer Genome Project 4
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Biology Products: